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1. Abstract 
     Lumbar spinal canal stenosis (LSCS) is one of the most common spinal disorders in 
elderly patients. Thickening of the ligamentum flavum has been considered a major 
contributor to the development of LSCS. Although previous studies have reported some 
growth factors, cytokines, matrix metalloproteinases (MMPs), and tissue inhibitors of matrix 
metalloproteinases (TIMPs) may play important roles in the pathogenesis of the thickened 
ligamentum flavum, its etiology is still unclear. The aim of this study was to analyze changes 
in the thickened ligamentum flavum and clarify their etiology.  
The ligamentum flavum samples were collected from 20 patients with LSCS (LSCS 
group) and 10 patients with lumbar disc herniation (LDH group) as a control. The thickness of 
the ligamentum flavum was measured histologically. The amount of elastic fibers and 
proteoglycans were assessed by Elastica-Masson staining and alcian blue staining, 
respectively. Gene and protein expressions related to elastogenesis, fibrosis, inflammation, 
chondrogenesis, and proteoglycan synthesis were analyzed by quantitative reverse 
transcription polymerase chain reaction and immunohistochemistry. The total genes of the 
two groups were compared by DNA microarray analysis. 
The thickness of the ligamentum flavum was significantly greater in the LSCS group 
compared with that in the LDH group. The amount of elastic fibers was smaller in the LSCS 
group and these changes were prominent on the dorsal side of the ligamentum flavum. 
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Staining intensity of alcian blue was significantly stronger in the LSCS group. The gene 
expressions related to elastogenesis were significantly lower in the LSCS group. The gene and 
expressions related to fibrosis were significantly higher in the LSCS group, however, the 
immunoreactivities of collagen types Ӏ and Ш were weaker on the dorsal side of the 
ligamentum flavum in the LSCS group. The gene and protein expressions related to 
chondrogenesis and proteoglycan synthesis were significantly higher in the LSCS group. 
There was no significant difference in the gene expressions related to inflammation between 
the two groups.     
Elastic fiber formation decreases in the ligamentum flavum of the patients with 
LSCS, which may lead to loss of elasticity. Synthesis of collagenous fibers and degradation of 
the elastic and collagenous fibers are both accelerated in the ligamentum flavum of patients 
with LSCS, which may be the reason for hypertrophy of the tissue. In addition, 
chondrogenesis and proteoglycan synthesis may have critical roles in the pathogenesis of the 
ligamentum flavum thickening. 
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2. Introduction 
Lumbar spinal canal stenosis (LSCS) is one of the most common spinal disorders in 
elderly patients. The concept of LSCS was made by Verbiest in 1954. He reported that 
narrowing of the bony vertebral canal caused neurological symptoms.
1
 It is estimated that 2.4 
million people have this disease in Japan. LSCS causes low back pain, leg pain and numbness, 
intermittent claudication, and urinary dysfunction by compression of the cauda equina and the 
nerve roots due to narrowing of the spinal canal, which leads to severe disability in the 
activities of daily living. Conservative treatments such as exercise, medication, and nerve 
block are performed and operation is needed in severe cases.
2,3
 LSCS occurs as a result of 
degenerative changes of the lumbar spine, including buldging of the intervertebral discs, bony 
proliferation of the facet joints, and thickening of the ligamentum flavum.
4,5
 The ligamentum 
flavum is a yellow elastic ligament which covers the posterior and lateral walls of the spinal 
canal and thickening of the ligamentum flavum has been considered as a major contributor to 
the development of LSCS.
6,7
 Altinkaya used the words “thickness” and “hypertrophy” 
differently. Thickness may increase by buckling without a change in the mass of the 
ligamentum flavum. The buckling of the ligamentum flavum into the spinal canal can occur 
after disc collapse.
8
 Although thickening of the ligamentum flavum is due to tissue 
hypertrophy or buckling, histologic changes leading to tissue hypertrophy have been reported, 
there remains a controversy.
7-9
 Previous studies have indicated that thickened ligamentum 
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flavum shows a loss of elastic fibers and an increase of collagen fibers.
4,9-11
 Therefore, fibrosis 
has been thought to be a main etiology of thickening of the ligamentum flavum and some 
factors related to fibrosis have been reported. Nakatani et al. reported that mechanical 
stretching force promoted TGF-1 production by ligamentum flavum cells which might lead 
to fibrosis of the ligament.
4
 Zhong et al. reported that connective tissue growth factor (CTGF) 
expression was higher in the thickened ligamentum flavum.
11
 Zhang et al. reported that higher 
platelet-derived growth factor-BB (PDGF-BB) existed in the thickened ligamentum flavum.
12
 
Park et al. reported that increased matrix metalloproteinases (MMPs) might be related to the 
elastin degradation and fibrosis of the ligamentum flavum.
13
 Park et al. also reported that 
increased tissue inhibitors of matrix metalloproteinases (TIMPs), especially TIMP-2, might 
cause fibrosis of the ligamentum flavum by inhibiting MMP activity.
10
 The reports of 
thickened ligamentum flavum are small in number and only a few except fibrosis. Yoshida et 
al. reported that Type ӀӀ collagen was identified in the thickened ligamentum flavum and 
chondrometaplasia might be one cause of thickening.
6
 Sairyo et al. reported that inflammatory 
cytokines were confirmed to be expressed in the ligamentum flavum and repetitive 
inflammation might cause scar accumulation, which would gradually lead to an increase in 
thickness.
14
 Though some growth factors, cytokines, MMPs, and TIMPs may play important 
roles in the pathogenesis of thickening of the ligamentum flavum, its mechanism is still 
unclear. Further, elastic fibers and proteoglycans have important roles in some pathological 
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conditions.
15,16
 Decrease of elastic fibers leads to a loss of the elasticity of tissues. It has been 
reported that elastic fibers are reduced and elastic system components are disrupted in normal 
and hypertrophic scars, which is similar to the conditions of the thickened ligamentum 
flavum.
17,18
 Some proteoglycans increase in fibrotic diseases including scars.
19
 Recent studies 
have indicated that accumulation of some glycosaminoglycans and proteoglycans relates to 
impaired elastic fiber formation.
20-22
 However, the changes of elastic fibers and proteoglycans 
in the thickened ligamentum flavum are not known.  
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3. Purpose 
The aim of this study was to elucidate the pathogenesis of the thickened ligamentum 
flavum using immunohistochemistry, quantitative reverse transcription polymerase chain 
reaction (qRT-PCR), and DNA microarray analysis. It will lead to development of prevention 
or new drug therapies for LSCS.    
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4. Materials and Methods 
4.1. Samples 
The protocols of this study were approved by institutional review boards of Takeda 
General Hospital (approval number; 2011-05). Twenty patients with LSCS necessitating 
decompressive surgery due to neurogenic claudication with thickening of the ligamentum 
flavum on magnetic resonance imaging (MRI) comprised the study group (LSCS group). The 
control group consisted of 10 patients with lumbar disc herniation (LDH) necessitating 
surgery without thickening of the ligamentum flavum on MRI (LDH group). The average age 
was 72.9 years (range 57-84, 10 males and 10 females) in the LSCS group and 64.6 years 
(range 47-77, 4 males and 6 females) in the LDH group. The difference of age distribution 
between the two groups was marginal but not statistically significant (P=0.0542). The 
thickness of the ligamentum flavum was evaluated using MRI (MAGNETOM Verio, 
3.0T-unit; Siemens, Erlangen, Germany, or Signa HDxt, 1.5T-unit, GE Healthcare, Milwaukee, 
WI) in supine position. On the T1-weighted axial images through the facet joint, the 
ligamentum flavum was clearly seen as a low-signal intensity mass just ventral side of the 
facet joint. A vertical line was drawn to the anterior side of the lamina to measure the 
thickness of the ligamentum flavum. The thickest portion of the ligamentum flavum was 
measured as thickness (Figure 1).  
4.2. Tissue preparation 
 9 
 
Fenestration was performed and the ligamentum flavum was obtained en-bloc during 
surgery. It was sagittally cut and evaluated histologically. The tissues were fixed with 4% 
paraformaldehyde (PFA) in 0.1 M phosphate buffered saline (PBS), pH 7.4 containing 18% 
sucrose for cryoprotection. The frozen tissue was cut into 5-m sections and was stained by 
following methods. The Elastica-Masson stained sections were used to evaluate the thickness 
of the ligamentum flavum and the amount of elastic fibers. The thickest portion of the 
ligamentum flavum was measured as a representative thickness. Regions of interest (ROI) in 
an area of 0.25 mm
2
 were selected from 10 sites in each ligamentum flavum: 5 on the dural 
side and 5 on the dorsal side as previously described.
9
 ROIs on each side were randomly 
selected (Figure 2). The area in dark purple color within the ROI, which corresponds to the 
ratio of elastic fibers, was calculated with use of ImageJ 1.47 software (National Institutes of 
Health, Besthesda, MD, USA). The amount of proteoglycans was assessed by alcian blue 
staining intensity. The changes of the elastic fibers were evaluated by high power images of 
Elastica-Masson staining and compositional changes of elastic fibers and proteoglycans were 
compared using these staining. 
4.3.  Immunohistochemistry (IHC) 
The sections were dried and post-fixed with 4% PFA for 10 minutes at room 
temperature, and immersed in 3.0% hydrogen peroxide for 10 minutes. The slides were 
incubated with 0.1% Trypsin 0.1% CaCl2/Tris Buffer at room temperature for 10 minutes. 
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Endogenous immunoglobulins were blocked by incubation with 10% normal goat serum 
(Nichirei, Tokyo, Japan) in PBS. The slides were incubated with antibodies (Table 1). The 
final detection step was carried out using 3, 3’-diaminobenzidine tetrahydrochloride (DAB, 
Sigma-Aldrich, St Louis, USA), 0.1 M imidazole, and 0.03% hydrogen peroxide. These slides 
were counterstained with hematoxylin. For negative controls, normal mouse, goat, or rabbit 
IgG was used as a primary antibody.       
4.4. RNA extraction and purification 
All the samples cut into small pieces were immediately placed in a vessel containing 
3-ml QIAzol (Qiagen, Hilden, Germany). They were stored immediately in a liquid nitrogen 
tank until RNA extraction. The frozen samples were homogenized with a Polytron
®
 
(Kinematica AD, Switzerland). The total RNA of the homogenate was purified using RNeasy 
Lipid Tissue Mini Kit (Qiagen) according to the manufacture’s instruction.  
4.5. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
Complementary DNA was synthesized using Cloned avian myeloblastis virus 
(AMV) first-strand cDNA synthesis kit (Invitrogen, Carlsbad, CA) according to the 
manufacture’s instruction. Gene expressions were evaluated quantitatively by real-time 
polymerase chain reaction (PCR) on a LightCycler (Roche Diagnostics, Basel, Switzerland). 
SYBR green was used for quantification of the amplified DNA. The cycling conditions were: 
95°C for 3 min, followed by 40 cycles of 95°C for 15 sec, 59°C for 30 sec and 72°C for 1 min. 
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At the end of the run, the melting temperature of the amplified product was measured to 
confirm its homogeneity. PCR efficiencies and relative expression levels of genes related to 
elastogenesis, fibrosis, inflammation, chondrogenesis, and proteoglycan synthesis as a 
function of elongation factor 11 (EF11) expression were calculated.23 The primer 
sequences for expression analyses are in Table 2, 3, and 4.  
4.6. DNA microarray analysis 
Eight LSCS samples and three LDH samples were used for DNA microarray analysis. 
After treatment with DNase Ӏ (Invitrogen), RNAs were amplified using Amino Ally 
MessageAmp ӀӀ aRNA Amplification Kit (Ambion, Austin, TX) and then labeled with Cy3 
and Cy5. Whole Human Genome Microarray Kit 4  44 K (Agilent, Santa Clara, CA) was 
applied to the Cy3- and Cy5-labeled amplified RNAs, which were then competitively 
hybridized at 65°C for 17 hours.
24
 The microarray was scanned with GenePix 4000B 
(Molecular Devices, Downingtown, PA). The scanned image was analyzed with GenePix Pro 
6 software (Molecular Devices). 
4.7. Statistical analyses 
Differences between the LSCS and LDH groups were compared by unpaired t-test 
(thickness) and by Mann–Whitney’s U test (age, qRT-PCR). Data were expressed as mean ± 
standard deviation (SD). Tests were two-sided and a value of P  0.05 was accepted as 
statistically significant. 
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5. Results 
5.1. Thickness of the ligamentum flavum 
On MRI, the mean thickness of the ligamentum flavum from the LSCS group (5.12 ± 
0.9 mm, range: 3.93-7.45) was significantly greater than that of the LDH group (2.93 ± 0.59 
mm, range: 1.69-3.73) (P  0.001). 
Histologically, the mean thickness of the ligamentum flavum from the LSCS group 
(4.77  0.79 mm, range: 3.91-7.16) was significantly greater than that from the LDH group 
(3.17  0.50 mm, range: 2.31-3.77) (P  0.001). 
5.2. Elastic fibers in the ligamentum flavum 
      The amount of elastic fibers was significantly smaller in the LSCS group, and these 
changes were prominent on the dorsal side of the ligamentum flavum. (Table 5, Figure 3A-D). 
Elastic fibers were thick and well regulated in the LDH group. However, they were sparse, 
thin, and fragmented in the LSCS group (Figure 4A and B). The gene expressions of 
fibrillin-2 and DANCE (fibulin-5) were significantly lower in the LSCS group compared with 
those in the LDH group. There was no statistical difference in the gene expressions of elastin, 
fibrillin-1, EMILIN-1, and fibulin-1 between the two groups (Table 6). 
5.3. Fibrosis and inflammation in the ligamentum flavum 
The gene expressions of COL1A2, COL3A1, CTGF, and Cysteine-rich angiogenic 
inducer 61 (CYR61) were significantly higher in the LSCS group. There was no statistical 
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difference in the gene expressions of COL1A1, TGF-1, PDGF-BB, -smooth muscle actin 
(-SMA), tumor necrosis factor (TNF)- and interleukin (IL)1- between the two groups 
(Table 7). The gene expressions of MMP-2 and TIMP-2 were significantly higher in the LSCS 
group. There were no statistical differences in the gene expressions of MMP-1, 3, 9, 13, and 
14, TIMP-1 and 3 between the two groups (Table 8). There was no apparent difference in 
immunoreactivities of collagen types Ӏ and Ш on the dural side between the two groups. 
However, the immunoreactivities were weaker on the dorsal side in the LSCS group (Figure 
5A-F). Immunoreactivities of CTGF and MMP-2 were stronger in the LSCS group (Figure 
6A-D). 
5.4. Chondrogenesis and proteoglycan synthesis in the ligamentum flavum 
The intensity of alcian blue staining was significantly stronger in the LSCS group. 
These changes were more evident on the dorsal side of the ligamentum flavum in accordance 
with the decreased elastic fibers (Figure 7A and B). The gene expressions of COL2A1, 
decorin, lumican, versican, and osteoglycin (OGN) were significantly higher in the LSCS 
group. There were no statistical differences in the gene expressions of COL10A1, SOX9, a 
disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) 4 and 5, aggrecan, 
biglycan, and fibromodulin between the two groups (Table 9). Immunoreactivities of collagen 
type ӀӀ, decorin, lumican, versican, and OGN were stronger in the LSCS group (Figure 8A 
and B, 9A-D, 10A-D). There was no apparent difference in immunoreactivities of aggrecan, 
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biglycan, and fibromodulin between the two groups (Figure 11A-F). 
5.5. Gene expression profiles 
To characterize microarray expression profiles, probes whose expressions changed 
by more than twofold up-regulation in the majority of the ligamentum flavum in the LSCS 
group or less than a half down-regulation in all the ligamentum flavum in the LSCS group 
compared with those in the ligamentum flavum in the LDH group were selected.
25
 The gene  
expressions of 12 genes were significantly higher (Table 10) and those of 22 genes 
were significantly lower (Table 11) in the LSCS group, among approximately 20,000 genes. 
Notably, fibrotic factors such as COL5A2 and COL1A2, chondrogenic factors such as 
COL11A1 and COL2A1 were significantly higher in the LSCS group. 
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6. Discussion 
The ligamentum flavum covers the posterior and lateral walls of the spinal canal. As 
the ligamentum flavum becomes thickened, it will compress the nerve roots and the cauda 
equina.
7
 Removal of the thickened ligamentum flavum is a main target of surgical treatment 
of LSCS.
12
 Some authors have evaluated the thickness of the ligamentum flavum using MRI 
or computed tomography (CT) and indicated that the ligamentum flavum is significantly 
thicker in LSCS.
10-12,26-28
 This study included the thickened ligamentum flavum on MRI 
(LSCS group) and non-thickened ligamentum flavum on MRI (LDH group). There have been 
no definition of thickening of the ligamentum flavum and there remained a possibility that the 
mild thickened ligamentum flavum was included in the LDH group. However, the results of 
the thickness of the ligamentum flavum in this study were almost same with the previous 
reports.
10-12,26-28
 Some authors have argued that the ligamentum flavum thickening is due to 
tissue hypertrophy, but others to the buckling of the ligamentum flavum.
5,8,11,26
 To confirm 
hypertrophy of the ligamentum flavum, we assessed the thickness of the ligamentum flavum 
histologically and it was significantly greater in the LSCS group. This result indicated that the 
ligamentum flavum was thickened in LSCS, which was due in part to tissue hypertrophy. MRI 
or CT images of the patients in this study can detect tissue hypertrophy together with buckling 
of the ligamentum flavum in the LSCS group.   
Elastic fibers are major components of the extracellular matrix in elastic connective 
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tissues such as large arteries, skin, lungs, and ligaments. They give these tissues resilience and 
elasticity to withstand repeated cycles of stretch and recoil through life.
29
 The two major 
structural components of elastic fibers are fibrillin-rich microfibrils and elastin, and other 
proteins control the process of their formation.
17,20
 Elastic fibers are reduced in pathological 
conditions, such as aortic aneurysms, pulmonary emphysema, and scars.
15,18
 Accelerated 
degradation or reduced synthesis of elastic fibers results in a loss of the elasticity of tissues.
30
 
The normal ligamentum flavum is a well-defined elastic structure with 80% elastic fibers and 
20% collagen fibers.
31
 Upon thickening, the ligamentum flavum shows a loss of elastic fibers 
and an increase of collagen fibers, resulting in fibrosis.
11
 Elastic fibers are made up of a 
central core of amorphous hydrophobic cross-linked elastin surrounded by fibrillin-rich 
microfibrils. Fibrillin is thought to act as a scaffold for the deposition of tropoelastin (the 
soluble precursor of mature elastin) onto microfibrils. DANCE is also required for elastic 
fiber assembly.
15,17,20
 Decreased expressions of fibrillin-2 and DANCE indicated disrupted 
elastogenesis in the thickened ligamentum flavum in this study. Sparse, thin, and fragmented 
elastic fibers might signify a disturbance in maturation in the thickened ligamentum flavum. 
Kosaka et al. divided the ligamentum flavum into 2 layers (dural and dorsal sides) and 
indicated that elastic fibers decreased mainly on the dorsal side.
9
 Sairyo et al. reported that the 
dorsal layer of the ligamentum flavum was always subjected to more load than the dural layer 
during lumbar motion. 
7
 They speculated that the ligamentum flavum thickening might be a 
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mechanically induced condition.  
The gene expressions of collagen types Ӏ and Ш were significantly higher in the 
LSCS group by qRT-PCR. These results indicated fibrotic process was prominent in the 
thickened ligamentum flavum. Some factors related to fibrosis, such as TGF-1, CTGF, and 
PDGF-BB, have been reported to be involved in the thickened ligamentum flavum.
11,12,26
 The 
gene expression of CTGF was significantly higher in the LSCS group. However, there was no 
statistical difference in the gene expressions of TGF-1 and PDGF-BB between the two 
groups in this study. Sairyo et al. reported the gene expression of TGF-1 decreased as the 
ligamentum flavum thickness increased. TGF-1 has been expressed only during the early 
phase of the scarring process and it might contribute to thickening of the ligamentum flavum 
during the early stages.
7
 LSCS is a disorder with a long duration and the expression of 
TGF-1 may depend on stages of LSCS. Zhang et al. divided the ligamentum flavum into 2 
layers (dural and dorsal layers) and reported higher gene expression of PDGF-BB in the 
dorsal layers.
12
 This result indicated that fibrogenic process might occur mainly on the dorsal 
side of the ligamentum flavum. There was no statistical difference of the gene expression of 
PDGF-BB between the two groups in this study. The layers of the LF were not divided in this 
study, which might make the difference smaller between the two groups. Regarding the 
angiogenic factors, CYR61 is highly expressed in granulation tissues during cutaneous wound 
healing.
32
 CYR61 drives fibroblasts into senescence and up-regulates the expression of 
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antifibrotic genes to restrict fibrosis during tissue repair.
33
 The gene expression of CYR61 was 
significantly higher in the LSCS group. This data supported an existence of fibrosis in the 
thickened ligamentum flavum. Inflammation has been considered to be the initial event which 
causes scar formation in the ligamentum flavum.
14
 However, there was no difference in the 
gene expressions of TNF- and IL1-between the two groups in this study. These results 
might depend on disease stages.      
 MMPs are a family of at least 24 peptidases that are collectively responsible for the 
degradation of extracellular matrix during tissue remodeling.
34,35
 TIMPs are the major 
endogenous regulators of MMPs activities in tissues, and four homologous TIMPs (TIMPs-1 
to 4) have been identified.
36
 Some MMPs and TIMPs, such as MMP-1, MMP-2, MMP-3, 
MMP-9, MMP-13, and TIMP-2 were reported to be increased in the thickened ligamentum 
flavum.
10,13,37
 The gene expressions of MMP-2 and TIMP-2 were significantly higher in the 
LSCS group, whereas the others were not significantly different between the two groups. 
Disease stages, differences of age distribution may have affected the results. MMP-2, which 
has an ability to degrade elastin, has been reported to be increased in human abdominal aortic 
aneurysm.
38
 The amount of elastic fibers in the LSCS group was smaller than in the LDH 
group. In addition, these changes were prominent on the dorsal side of the ligamentum flavum. 
Up-regulated MMP-2 might be associated with a loss of elastic fibers in the thickened 
ligamentum flavum. MMP-2 is well-known as a gelatinase and digests denatured collagens. 
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Some authors have reported that MMP-2 also has an ability to digest interstitial collagens.
35,39
 
Though the gene expressions of collagen types Ӏ and Ш were significantly higher in the LSCS 
group, the immunoreactivities of collagen types Ӏ and Ш were weaker on the dorsal side of 
the ligamentum flavum in the LSCS group. These contradictory results were explained by the 
ability of MMP-2 to digest collagens. Up-regulated MMP-2 might degrade increased 
collagens and TIMP-2 is the major inhibitor of MMP-2.
40
 Collagen synthesis and degradation 
might be accelerated in the thickened ligamentum flavum, which might lead to scar 
formation. 
Proteoglycans consist of a core protein to which at least one glycosaminoglycan 
chain is attached. They maintain the structure of the extracellular matrix and play important 
roles in the physiology and biomechanical function of tissues.
16,41
 Alcian blue staining 
intensity was stronger in the LSCS group. This result supported increased proteoglycans in 
the thickened ligamentum flavum as previously reported.
42
 And the gene expression of 
collagen type ӀӀ was significantly higher in the LSCS group. These results indicated 
chondrogenic process in the thickened ligamentum flavum. These changes have been also 
reported to occur at the insertion site of the other ligaments and considered as a mechanical 
response.
6,9
 There was no significant difference in the gene expressions of SOX9, aggrecan, 
and COL10A1, which were specific in the articular cartilage, between the two groups. These 
results indicated that the chondrogenic gene expression patterns in the thickened ligamentum 
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flavum were different from those in the articular cartilage. Proteoglycans are divided into two 
main groups, small leucine-rich proteoglycans (SLRPs) and large proteoglycans by the size of 
their core proteins. Decorin, lumican, and osteoglycin are members of SLRPs and versican 
belongs to large proteoglycans.
16
 They are detected in cartilage matrix during 
chondrogenesis.
43,44
 The gene expressions of decorin, lumican, osteoglycin, and versican were 
significantly higher in the LSCS group. These results might support chondrogenic process in 
the thickened ligamentum flavum. There remains other possibility in pathogenesis of 
increased proteoglycans. Increased proteoglycans have been reported to be associated with 
pathological processes, such as wound healing, organ fibrosis, and tumor 
development.
16,41,45-47
 An increased decorin expression has been shown in tissues of some 
fibrotic diseases, such as postmyocardial infarction, liver fibrosis, and renal fibrosis.
48-50
 
Lumican has been reported to increase in cardiac fibrosis and tumors.
46,51
 Versican has been 
reported to increase in many diseases, such as inflammatory lung disorders, hypertrophic 
scars, and tumors.
19,52,53
 Increased versican has also been detected in injured ligaments.
54
 
Though there have been few reports of increased osteoglycin, it has been reported that 
osteoglycin regulates cellular growth and an increased expression deceases the metastatic 
capability of mouse hepatocarcinoma.
55,56
 Proteoglycans, such as decorin, lumican, 
osteoglycin, and versican increased in the LSCS group in this study. And these changes were 
prominent on the dorsal side of the ligamentum flavum in accordance with the decreased 
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elastic fibers. These proteoglycans increase in the repair process or fibrotic conditions as 
described above. Our results supported the theory that thickening of the ligamentum flavum is 
a result of micro tissue injuries due to lumbar motion.
7
 Mechanical stress during lumbar 
motion might cause repetitive injury and subsequent accelerated healing process might 
increase proteoglycans in the ligamentum flavum. Chondrogenic process and proteoglycan 
synthesis might be one of the main etiologies of the thickened ligamentum flavum. 
       Considering increased proteoglycans, there are other possibilities in the pathogenesis 
of the ligamentum flavum thickening. Decorin inhibits TGF- which plays a central role in 
fibrosis, and TGF-upregulates decorin production.45,57 Decorin is reduced in repairing 
ligaments and postburn hypertrophic scars, leading to TGF-activation and fibrosis.54,58 
However, the expression of decorin during wound repair is very complex. Sayani et al. 
reported that the expression of decorin in burn wounds is low up to a year and increases from 
1 to 3 years after the injury.
59,60
 An increased decorin expression has been shown in tissues of 
some fibrotic diseases.
48-50
 These results mean that decorin has a protective role in organ 
fibrogenesis by inhibiting TGF-activity.45 Sairyo et al. reported that the expression of 
TGF-and ligamentum flavum thickness show a negative linear relationship.7 LSCS is a 
disease with a long duration and an increased decorin may inhibit TGF-activity in the 
thickened ligamentum flavum. Ikeda et al. reported that elastic fiber assembly is disrupted by 
excessive accumulation of chondroitin sulphate glycosaminoglycans in keloid lesions.
20
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Hinek et al. reported that Hurler disease causes accumulation of dermatan sulfate 
glycosaminoglycans, which impairs elastogenesis by inhibition of elastic fiber assembly.
22
 
Chondroitin sulfate and dermatan sulfate are chains of decorin and versican.
16
 Chronic 
obstructive pulmonary disease is characterized by a loss of elastic fibers in the alveolar wall 
and these changes are considered to be related to increased versican.
21
 Increased 
proteoglycans might inhibit elastic fiber assembly, which accelerated the loss of elastic fibers, 
and increase the thickness of the ligamentum flavum. Decreased elasticity may cause 
buckling of the ligamentum flavum.      
 From DNA microarray analysis, gene expressions related to fibrosis, such as 
COL5A2 and COL1A2, chondrogenesis, such as COL11A1 and COL2A1, were significantly 
higher in the LSCS group. Considering other genes in the microarray analysis, there are some 
possibilities in the pathogenesis of the ligamentum flavum thickening. The gene expression of 
OGN was significantly higher in the LSCS group alike to the result of qRT-PCR. The WNT1 
inducible signaling pathway protein 1 (WISP1) and fibronectin (FN) are expressed in fibrotic 
disorders.
61,62
 The gene expressions of WISP1 and FN were significantly higher in the LSCS 
group. These data might support fibrogenic process in the thickened ligamentum flavum. 
Dipeptidyl peptidase-4 (DPP4) is reported to degrade denatured collagen.
63
 The gene 
expression of DPP4 was significantly higher in the LSCS group. This data might support 
collagen degradation process in the thickened ligamentum flavum.     
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       Limitations of this study are as follows: (1) the samples were contracted while 
immersed in PFA for tissue preparations, (2) the average age of the LSCS group was higher 
than the LDH group and we cannot exclude the possibility that the natural aging process 
affected the results, (3) LSCS is a disease with a long duration. Samples might be obtained 
from several stages of the disease and affect the results, (4) protein expressions are not 
evaluated quantitatively.    
My hypothesis of the pathogenesis of the thickened ligamentum flavum obtained 
from this study is as follows: (1) mechanical stress during lumbar motion causes repetitive 
injury of ligamentum flavum, which leads to degradation of elastic fibers and coexistence of 
synthesis and degradation of collagen fibers, (2) accelerated healing process causes 
accumulation of proteoglycans which leads to chondrometaplasia, (3) decreased elastogenesis 
and disrupted elastic fiber assembly caused by increased proteoglycans leads to loss of elastic 
fibers, (4) hypertrophy of the tissue due to accumulation of the extracellular matrix in this 
process and buckling of the tissue due to loss of elasticity causes thickening of the 
ligamentum flavum (Figure 12). 
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7. Conclusion 
In conclusion, the present study suggested as follows: (1) The ligamentum flavum was 
thickened in LSCS, which was due in part to tissue hypertrophy, (2) Elastic fibers decreased 
in the thickened ligamentum flavum. Increased MMP-2 might be associated with a loss of 
elastic fibers. Further, Fibrillin-2 and DANCE decreased in the thickened ligamentum flavum, 
which indicated decreased elastogenesis, (3) The gene expressions of COL1A2, COL3A1, 
CTGF, and CYR61 increased in the thickened ligamentum flavum, which indicated fibrosis, 
(4) Immunoreactivities of collagen type Ӏ and Ш were weaker on the dorsal side of the 
thickened ligamentum flavum, which indicated degradation of collagen fibers. Increased 
MMP-2 might degrade increased collagen fibers, (5) TIMP-2 also increased in the thickened 
ligamentum flavum, which might inhibit MMP-2. Collagen synthesis and degradation might 
be accelerated in the thickened ligamentum flavum like scar formation, (6) Proteoglycans, 
such as decorin, lumican, versican, and osteoglycin increased in the thickened ligamentum 
flavum. These proteoglycans might increase in the process of accelerated collagen synthesis 
and degradation, (7) Collagen type ӀӀ increased in the thickened ligamentum flavum, which 
indicated chondrometaplasia along with increased proteoglycans, (8) Increased proteoglycans 
might inhibit elastic fiber assembly and accelerate the loss of elastic fibers. Decreased 
elasticity may cause buckling of the ligamentum flavum, (9) DNA microarray analysis was 
performed. The expressions of 12 genes increased in the thickened ligamentum flavum among 
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approximately 20,000 genes. Notably, fibrotic factors such as COL5A2 and COL1A2, 
chondrogenic factors such as COL11A1 and COL2A1, and OGN increased in the thickened 
ligamentum flavum. 
Thickening of the ligamentum flavum is due to hypertrophy and a loss of elasticity of 
the tissue. Accumulated proteoglycans are thought to be associated with these changes. 
Decomposing proteoglycans could be a novel therapy for LSCS and should be analyzed in the 
future study. 
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10. Figure Legends 
Figure 1. The thickness of the ligamentum flavum on MRI. A: Lumbar spine on MRI. B: 
Measuring of the thickness of the ligamentum flavum. On the T1-weighted axial images of 
the ligamentum flavum through the facet joint, the ligamentum flavum was clearly seen as a 
low-signal intensity mass just ventral side of the facet joint. The area surrounded by yellow 
line indicated ligamentum flavum. Arrow head indicated lamina (A). A vertical line to the 
anterior side of the lamina was made to measure the thickness of the ligamentum flavum 
(white line). The thickest portion of the ligamentum flavum was measured as thickness 
(yellow line) (B). 
 
Figure 2. Evaluation of the thickness and the amount of elastic fibers in the ligamentum 
flavum. A: Elastica-Masson staining of the ligamentum flavum in lumbar disc herniation 
(LDH), B: lumbar spinal canal stenosis (LSCS). The thickest portion of the ligamentum 
flavum was measured as a representative thickness. The area in dark purple color within the 
region of interest (ROI), which corresponds to the ratio of elastic fibers, was calculated. White 
line indicated a thickness. The area surrounded by broken lines indicated ROI. Scale bars: 500 
m.  
 
Figure 3. Elastic fibers in the ligamentum flavum. A: Elastica-Masson staining of dural side 
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of the ligamentum flavum in LDH, B: LSCS, C: dorsal side in LDH, D: LSCS. Elastic fibers 
were significantly smaller in LSCS group compared with the LDH group and that change was 
evident on the dorsal side of the ligamentum flavum. Dark purple areas indicated elastic fibers 
(A-D). Scale bars: 200 m. 
 
Figure 4. High power images of elastic fibers in the ligamentum flavum. A: High power 
images of Elastica-Masson staining of the ligamentum flavum in LDH, B: LSCS. Elastic 
fibers were thick and well regulated in the LDH group and sparse, thin, and fragmented in the 
LSCS group (A and B). Scale bars: 50 m. Arrows indicated elastic fibers. 
 
Figure 5. Immunostainings of collagen types Ӏ and Ш in the ligamentum flavum. A: 
Immunoreactivity of collagen type Ӏ in LDH, B: dural side of LSCS, C: dorsal side of LSCS, 
D: collagen type Ш in LDH, E: dural side of LSCS, F: dorsal side of LSCS. 
Immunoreactivities of collagen types Ӏ and Ш, which were stained brown, were not 
significantly different on the dural side of the ligamentum flavum between the LSCS group 
and the LDH group (A, B, D, E). They were weaker on the dorsal side of the ligamentum 
flavum in the LSCS group (C and F). Scale bars: 200 m. 
 
Figure 6. Immunostainings of CTGF and MMP-2 in the ligamentum flavum. A: 
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Immunoreactivity of CTGF in LDH, B: LSCS, C: MMP-2 in LDH, D: LSCS. Strong 
immunoreactivities of CTGF and MMP-2 were detected in the LSCS group (A-D). Scale bars: 
200 m. Arrow heads: immunoreactivities of CTGF and MMP-2. 
 
Figure 7. Proteoglycans in the ligamentum flavum. A: alcian blue staining of the ligamentum 
flavum in LDH, B: LSCS. The intensity of alcian blue staining was significantly stronger in 
the LSCS group compared with the LDH group. These changes were evident on the dorsal 
side of the ligamentum flavum (A and B). Arrows indicated the dorsal side of the ligamentum 
flavum. Scale bars: 500 m. 
 
Figure 8. Immunostaining of collagen type ӀӀ in the ligamentum flavum. A: Immunoreactivity 
of collagen type ӀӀ in LDH, B: LSCS. Strong immunoreactivity of collagen type ӀӀ was 
detected as a spotted area in the LSCS group (A and B). Scale bars: 200 m. Arrow heads: 
immunoreactivities of collagen type ӀӀ. 
 
Figure 9. Immunostainings of decorin and lumican in the ligamentum flavum. A: 
Immunoreactivity of decorin in LDH, B: LSCS, C: lumican in LDH, D: LSCS. Strong 
immunoreactivities of decorin and lumican were detected in the LSCS group, especially on 
the dorsal side (A-D). Scale bars: 200 m. Arrows indicated the dorsal side of the ligamentum 
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flavum. Arrow heads indicated immunoreactivities of decorin and lumican. 
 
Figure 10. Immunostainings of versican and osteoglycin in the ligamentum flavum. A: 
Immunoreactivity of versican in LDH, B: LSCS, C: osteoglycin in LDH, D: LSCS. Strong 
immunoreactivities of versican and osteoglycin were detected in the LSCS group, especially 
on the dorsal side (A-D). Scale bars: 200 m. Arrows indicated dorsal side of the ligamentum 
flavum. Arrow heads indicated immunoreactivities of versican and osteoglycin. 
 
Figure 11. Immunostainings of aggrecan, biglycan, and fibromodulin in the ligamentum 
flavum. A: Immunoreactivity of aggrecan in LDH, B: LSCS, C: biglycan in LDH, D: LSCS, 
E: fibromodulin in LDH, F: LSCS. There were no apparent difference in immunoreactivities 
of aggrecan, biglycan, and fibromodulin between the two groups (A-F). Scale bars: 200 m. 
 
Figure 12. Hypothesis of the pathogenesis of thickening of the ligamentum flavum. 
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Figure 12.  
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Table 1.  
  
 Antibody  Cat. No.  Products  Dilution
 Polyclonal rabbit anti-human collagen type Ӏ antibody  ab34710  Abcam  1:200
 Monoclonal mouse anti-human collagen type Π antibody  ab3092  Abcam  1:200
 Polyclonal rabbit anti-human collagen type Ш antibody  ab7778  Abcam  1:400
 Polyclonal rabbit anti-human CTGF antibody  ab6992  Abcam  1:200
 Polyclonal rabbit anti-human MMP-2 antibody  ab37150  Abcam  1:200
 Monoclonal mouse anti-human decorin antibody  ab54728  Abcam  1:800
 Polyclonal goat anti-human lumican antibody  AF2846  R & D  1:40
 Polyclonal rabbit anti-human versican antibody  ab19345  Abcam  1:200
 Polyclonal rabbit anti-human OGN antibody  HPA013132  Sigma  1:100
 Monoclonal mouse anti-human aggrecan antibody  Ab3778  Abcam  1:50
 Polyclonal goat anti-human biglycan antibody  ab58562  Abcam  1:100
 Polyclonal rabbit anti-human fibromodulin antibody  ab81443  Abcam  1:200
 
 
 
 
 
 
 
 
 
 
 Primary antibodies and their dilution. 
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Table 2.  
 
 Gene Name  GenBank  Nucleic acid sequences
 COL1A1 Z74615  Upstream CGAGGGCCAAGACGAAGACATC 
     Downstream GGGCAGACGGGACAGCACTC 
 COL1A2 NM_000089  Upstream TGGTGGTTATGACTTTGGTTACGA 
     Downstream CATGTGCGAGCTGGTTCTT 
 COL2A1 NM_001844  Upstream ATCCGGGCAGAGGGCAATAG 
     Downstream ATGATGGGGAGGCGTGAGGT 
 COL3A1 NM_000090  Upstream TGAAGGGCAGGGAACAACT 
     Downstream CCGCATAGGACTGACCAAGAT 
 COL10A1 NM_000493  Upstream CAGCTTCCCAATGCCGAGTCA 
     Downstream TGCATTTTGTAGGGTGGGGTAGAGTT 
EF1  1 NM_001402  Upstream GGTCGCTTTGCTGTTCGTGAT 
     Downstream AGAGTGGGGTGGCAGGTATTAGG 
TGF-  1 NM_000660  Upstream AGGACCTCGGCTGGAAGTGGAT 
     Downstream AGGCGCCCGGGTTATGCT 
  SMA NM_001613  Upstream CTATCAGGGGGCACCACTATGT 
     Downstream CTCCGGAGGGGCAATGA 
 CTGF NM_001901  Upstream GAAGAGAACATTAAGAAGGGCAAAAAG 
     Downstream CCGGCAGGGTGGTGGTT 
 CYR61 NM_001554  Upstream GCTGCGGCTGCTGTAAGGTCT 
     Downstream  CCCACGGCGCCATCAATA
 PDGF-BB NM_002608  Upstream TAGGGGCATCGGCAGGAGA 
     Downstream ATGGGGGCAATACAGCAAATACC 
TNF-   NM_000594  Upstream ACCCACGGCTCCACCCTCTC 
     Downstream ACGTCCCGGATCATGCTTTCAG 
IL-1   NM_000576  Upstream AGGCCGCGTCAGTTGTTGT 
     Downstream CCGGAGCGTGCAGTTCAGT 
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Table 3.  
 
Gene 
 Name
 GenBank  Nucleic acid sequences
 MMP-1 NM_002421  Upstream TGTTCTGGGGTGTGGTGTCTCA 
     Downstream TTCAACTTGCCTCCCATCATTCTT 
 MMP-2 NM_004530  Upstream ACGCTGGGCCCTGTCACTC 
     Downstream GGGCCTCGTATACCGCATCA 
 MMP-3 NM_002422  Upstream TGACCCAAATGCAAAGAAAGTGA 
     Downstream ATAAAAATGACCGGCAAGATACAGAT 
 MMP-9 NM_004994  Upstream TGCCCGGACCAAGGATACAGT 
     Downstream TCAGGGCGAGGACCATAGAGG 
 MMP-13 NM_002427  Upstream GAAGACCCCAACCCTAAACATCC 
     Downstream TAAAAACAGCTCCGCATCAACCT 
 MMP-14 NM_004995  Upstream CGGGGCATCCAGCAACTTTAT 
     Downstream CCTCACCCGCCAGAACCAG 
 TIMP-1 NM_003254  Upstream CCTGGCTTCTGGCATCCTGT 
     Downstream GGCGGGGGTGTAGACGAA 
 TIMP-2 NM_003255  Upstream CAAAGCGGTCAGTGAGAAGGAAG 
     Downstream AGGAGGGGGCCGTGTAGATAA 
 TIMP-3 NM_000362  Upstream TTGGAGGGCCGATGAGGTAA 
     Downstream CTGGGCGGCCGAGTGATA 
 ADAMTS4 NM_005099  Upstream GCGGAGGGGACGGTTCT 
     Downstream TGTGGGGGAGGGCATCA 
 ADAMTS5 NM_007038  Upstream CAAGAACGCTGCCACCACAC 
     Downstream GGAGGCCATCGTCTTCAATCA 
 SOX9 NM_000346  Upstream GCGGAGCTCGAAACTGACTG 
     Downstream TACCGCGGCGAGCACTTAG 
 
 
 
 
 Polymerase chain reaction primer sequences.
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Table 4.  
 
 Gene Name  GenBank  Nucleic acid sequences
 elastin NM_001081753  Upstream GGACCCCTGACTCACGACCTC 
     Downstream  TGGCCGCTCCCCTCTTGT
 fibrillin-1 NM_000138  Upstream  TGCCCTGGATGGAAAACCTTAC
     Downstream  CCGGCAAATGGGGACAATAC
 fibrillin-2 NM_001999  Upstream  GCCCGGCAGCAAACTCAG
     Downstream  AGGGTGGCACAGCATTCAGATT
 fibulin-1 NM_001996  Upstream  TCGGGGGCCTCCAAGAAA
     Downstream  CTCCTCGGCAGCGGTCATT
 EMILIN-1 NM_007046  Upstream  GCGGGGCCCTGCTCTATG
     Downstream  CGCCCCCGCTGTCTCTTC
 DANCE NM_006329  Upstream  CCACCCCCAGTTCCTATGACA
     Downstream  GACCCCCGCAAACCTAATCTAT
 decorin  NM_001920  Upstream  TGCCCACCTGGACACAACAC
     Downstream  GCAGAGCGCACGTAGACACAT
 biglycan  NM_001702  Upstream  CTCCTCCAGGTGGTCTATCT
     Downstream  GGTTGTTGAAGAGGCTGATG
 lumican  NM_002345  Upstream  CTTCAATCAGATAGCCAGACTGC
     Downstream  AGCCAGTTCGTTGTGAGATAAAC
 fibromodulin  NM_002023  Upstream TGCTGGAATTCCCAACTTCCTCACG
 GCCATGT
     Downstream CTCGAGCGGCCGCAACTCATTGATC
 CTATTGCCT
 osteoglycin  NM_033014  Upstream  CCCTGGAATCCGTGCCTCTT
     Downstream  TGCGGTCCCGGATGTAACTG
 aggrecan  NM_013227  Upstream  GCCTGCGCTCCAATGACTC
     Downstream  TGGCAATGATGGCACTGTTCT
 versican  NM_004385  Upstream  TGGAATGATGTTCCCTGCAA
     Downstream  AAGGTCTTGGCATTTTCTACAACAG
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Table 5.  
 
(%)                                                             
   LDH  LSCS  P
 Dural side 72.44    4.73 64.07    9.47  0.018
 Dorsal side 68.48    7.08 49.66    7.16  0.00074
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Table 6.  
 
     Mean ± SD  P
 elastin  LSCS 0.74    0.37  0.23
   LDH 1.44    1.55   
 fibrillin-1  LSCS 1.87    2.62  0.55
   LDH 1.59    1.36   
 fibrillin-2  LSCS 0.59    0.31  0.016
   LDH 1.18    0.70   
 EMILIN-1  LSCS 0.85    0.48  0.19
   LDH 1.15    0.65   
 fibulin-1  LSCS 7.04    11.44  0.42
   LDH 4.14    7.07   
 DANCE  LSCS 0.81    0.23  0.036
   LDH 1.05    0.35                   
 
 
 
 
 
 
 
 
 
 
 Gene expressions of elastogenesis in the ligamentum flavum.
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Table 7. 
 
     Mean ± SD  P
 COL1A1  LSCS  1.40 ± 1.63  0.54
   LDH  1.01±0.41   
 COL1A2  LSCS  2.88 ± 2.81  0.023
   LDH  1.09 ± 0.46   
 COL3A1  LSCS  14.18 ± 20.01  0.047
   LDH  4.21 ± 7.61   
TGF-    LSCS  1.47 ± 0.86  0.38
   LDH  1.09 ± 0.43   
 CTGF  LSCS  1.70 ± 0.78  0.043
   LDH  1.11 ± 0.54   
 PDGF-BB  LSCS  2.27 ± 2.08  0.21
   LDH  1.57 ± 1.63   
  -SMA  LSCS  2.46 ± 2.71  0.084
   LDH  1.54 ± 1.67   
 CYR61  LSCS  4.16 ± 3.52  0.012
   LDH  1.35 ± 1.25   
TNF-    LSCS  0.78 ± 0.59  0.17
   LDH  1.42 ± 1.13   
IL1-    LSCS  0.78 ± 0.44  0.17
   LDH  1.35±1.01   
 
 
 
 
 
 
 
 
 Fibrotic and inflammatory gene expressions in the ligamentum flavum.
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Table 8.  
 
    Mean    SD  P
 MMP-1  LSCS  1.09 ± 0.54  0.56
   LDH  1.37 ± 1.04   
 MMP-2  LSCS  2.70 ± 1.81  0.039
   LDH  1.38 ± 1.10   
 MMP-3  LSCS  1.10 ± 0.83  0.48
   LDH  1.08 ± 0.38   
 MMP-9  LSCS  1.63 ± 1.75  0.25
   LDH  1.21 ± 1.27   
 MMP-13  LSCS  7.99 ± 11.54  0.51
   LDH  3.46 ± 3.91   
 MMP-14  LSCS  2.64 ± 3.56  0.34
   LDH  1.32 ± 0.82   
 TIMP-1  LSCS  2.26 ± 2.10  0.076
   LDH  1.07 ± 0.72   
 TIMP-2  LSCS  4.25 ± 2.20  0.044
   LDH  2.37 ± 2.25   
 TIMP-3  LSCS  1.59 ± 1.73  0.50
   LDH  2.07 ± 1.99   
 
 
 
 
 
 
 
 
 Gene expressions of MMPs and TIMPs in the ligamentum flavum.
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Table 9.  
 
     Mean ± SD  P
 COL2A1  LSCS  1.99 ± 1.42  0.043
   LDH  0.88 ± 0.43   
 COL10A1  LSCS  0.72 ± 0.47  0.11
   LDH  1.22 ± 0.82   
 SOX9  LSCS  1.01 ± 0.90  0.30
   LDH  1.67 ± 1.54   
 ADAMTS4  LSCS  0.92 ± 0.74  0.54
   LDH  1.03 ± 0.73   
 ADAMTS5  LSCS  0.80 ± 0.47  0.093
   LDH  1.22 ± 0.67   
 aggrecan  LSCS  1.05 ± 1.21  0.30
   LDH  1.24 ± 0.84   
 decorin  LSCS  3.33 ± 2.38  0.020
   LDH  1.25 ± 1.19   
 biglycan  LSCS  1.64 ± 0.96  0.11
   LDH  1.05 ± 0.73                   
 lumican  LSCS  3.91 ± 4.02  0.02
   LDH  1.38 ± 1.33   
 fibromodulin  LSCS  2.23 ± 2.17  0.25
   LDH  0.99 ± 0.81   
 versican  LSCS  11.50 ± 12.43  0.02
   LDH  2.98 ± 3.76   
 osteoglycin  LSCS  4.34 ± 5.70  0.048
   LDH  2.07 ± 2.39   
 
 
 
 
 
Gene expressions of  chondrogenesis and proteoglycans in the ligamentum flavum.
 62 
 
Table 10.  
 
 GenBank  Gene Name  Description
 NM_001190709  COL11A1  Homo sapiens collagen, typeΧΙ, alpha1
 NM_033150  COL2A1  Homo sapiens collagen, typeП, alpha1
 NM_130830  LRRC15  Homo sapiens leucine rich repeat containing 15
 NM_000624  SERPINA5 Homo sapiens serpin peptidase inhibitor, clade A  
 (alpha-1 antiproteinase, antitrypsin), member 5
 NM_014057  OGN  Homo sapiens osteoglycin
 NM_001935  DPP4  Homo sapiens dipeptidyl-peptidase 4
 NM_003882  WISP1 Homo sapiens WNT1 inducible signaling pathway 
 protein 1
 NM_000393  COL5A2  Homo sapiens collagen, typeV, alpha 2
 NM_001252  CD70  Homo sapiens CD70 molecule
 NM_152282  ACPL2  Homo sapiens acid phosphatase-like 2
 NM_212474  FN1  Homo sapiens fibronectin 1
 NM_000089  COL1A2  Homo sapiens collagen, typeΙ, alpha2
 
 
 
 
 
 
 
 
 
 
 Increased gene profiles in microarray analysis.
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Table 11.  
 
 GenBank   Gene Name  Description
 NM_000432  MYL2   Homo sapiens myosin, light chain 2, regulatory, cardiac, slow, 
 mRNA
 NM_001824  CKM  Homo sapiens creatine kinase, muscle, mRNA 
 NM_001100  ACTA1     Homo sapiens actin, alpha 1, skeletal muscle, mRNA
 NM_144994  ANKRD23    Homo sapiens ankyrin repeat domain 23, mRNA
 NM_003476  CSRP3  Homo sapiens cysteine and glycine-rich protein 3 (cardiac LIM 
 protein), transcript variant 1, mRNA
 NM_203377   MB  Homo sapiens myoglobin, transcript variant 2, mRNA
 NM_016599  MYOZ2  Homo sapiens myozenin 2, mRNA
 NM_001890  CSN1S1  Homo sapiens casein alpha s1 (CSN1S1), transcript variant 1, 
 mRNA
 NM_000257  MYH7    Homo sapiens myosin, heavy chain 7, cardiac muscle, beta, mRNA
 NM_003279  TNNC2   Homo sapiens troponin C type 2 (fast), mRNA 
 NM_003673    TCAP   Homo sapiens titin-cap (telethonin), mRNA
 NM_003280  TNNC1    Homo sapiens troponin C type 1 (slow), mRNA 
 NM_001126132  TNNT1      Homo sapiens troponin T type 1 (skeletal, slow), transcript variant 
 2, mRNA 
 NM_001927  DES  Homo sapiens desmin, mRNA 
 NM_001976  ENO3 Homo sapiens enolase 3 (beta, muscle), transcript variant 1, 
 mRNA
 NM_003282    TNNI2 Homo sapiens troponin I type 2 (skeletal, fast), transcript variant 1, 
 mRNA
 NM_020349  ANKRD2   Homo sapiens ankyrin repeat domain 2 (stretch responsive 
 muscle), transcript variant 1, mRNA
 NM_053044   HTRA3     Homo sapiens HtrA serine peptidase 3, mRNA 
 NM_001231  CASQ1 Homo sapiens calsequestrin 1 (fast-twitch, skeletal muscle), 
 nuclear gene encoding mitochondrial protein, mRNA
 NM_000037  ANK1   Homo sapiens ankyrin 1, erythrocytic, transcript variant 3, mRNA 
 NM_002475  MYL6B Homo sapiens myosin, light chain 6B, alkali, smooth muscle and 
 non-muscle, transcript variant 2, mRNA
 NM_004102    FABP3  Homo sapiens fatty acid binding protein 3, muscle and heart 
 (mammary-derived growth inhibitor) (FABP3), mRNA 
 
 Decreased gene profiles in microarray analysis.
